2018
DOI: 10.1002/acr.23534
|View full text |Cite
|
Sign up to set email alerts
|

Characterization of Patients With Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis in the US‐Based Corrona Registry

Abstract: ObjectiveTo describe the characteristics of patients with ankylosing spondylitis (AS) and patients with nonradiographic axial spondyloarthritis (SpA) in the US.MethodsDemographics, clinical characteristics, patient‐reported outcomes, and treatment characteristics of patients with AS and those with nonradiographic axial SpA were assessed at the time of enrollment in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. Patients with AS were defined as those who fulfilled the 1984 modified New York criteri… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

5
43
0
4

Year Published

2019
2019
2022
2022

Publication Types

Select...
10

Relationship

1
9

Authors

Journals

citations
Cited by 62 publications
(52 citation statements)
references
References 41 publications
5
43
0
4
Order By: Relevance
“…Evidence is accumulating from observational studies that tumour necrosis factor inhibitors (TNFi) might retard spinal damage, if treatment is continued for several years [11][12][13][14]. Very limited data on spinal radiographic progression exists for the nonradiographic disease form (nr-axSpA) [4,10], an entity differentiated from r-axSpA by the absence of definite sacroiliac damage on radiographs [15,16], according to the modified New York criteria (mNYc) [5], but presenting from a clinical point of view, a burden of disease comparable to r-axSpA despite lower spinal structural damage [17][18][19][20][21][22][23]. It remains, however, unclear whether radiographic sacroiliitis is by itself associated with progression of spinal structural damage.…”
Section: Introductionmentioning
confidence: 99%
“…Evidence is accumulating from observational studies that tumour necrosis factor inhibitors (TNFi) might retard spinal damage, if treatment is continued for several years [11][12][13][14]. Very limited data on spinal radiographic progression exists for the nonradiographic disease form (nr-axSpA) [4,10], an entity differentiated from r-axSpA by the absence of definite sacroiliac damage on radiographs [15,16], according to the modified New York criteria (mNYc) [5], but presenting from a clinical point of view, a burden of disease comparable to r-axSpA despite lower spinal structural damage [17][18][19][20][21][22][23]. It remains, however, unclear whether radiographic sacroiliitis is by itself associated with progression of spinal structural damage.…”
Section: Introductionmentioning
confidence: 99%
“…This debate is particularly important in North America, where the Food and Drug Administration expressed several concerns about the incompletely characterisation of the natural history of axSpA, which led to the non-approval of several biological disease-modifying antirheumatic drugs (bDMARDs) to treat patients with nr-axSpA 3. These questions resulted in the publication of some studies that compare these two groups of patients, showing a similar disease burden but a higher prevalence of males and smokers, a larger mean disease duration and a higher level of acute phase reactants in r-axSpA patients 4–8. However, most of these studies have a cross-sectional design which does not allow us to understand the natural history of these two subgroups.…”
Section: Introductionmentioning
confidence: 99%
“…Following the footsteps of treat‐to‐target strategies in rheumatoid arthritis, there has been an increasing emphasis to treat inflammatory back pain early, which may halt disease progression and prevent chronic damage. Some cohorts of SpA such as GESPIC, Herne, DESIR and Corrona have shown similar clinical characteristics of AS and nr‐AxSpA, as well as notable differences. For instance, AS patients were predominantly male, having higher C‐reactive protein (CRP) and Bath Ankylosing Spondylitis Metrology Index (BASMI) scores compared to nr‐axSpA patients.…”
Section: Introductionmentioning
confidence: 99%